Citations (29)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Michael Harris, Simon Erridge, Mehmet Ergisi, Devaki Nimalan, Michal Kawka, Oliver Salazar, Rayyan Ali, Katerina Loupasaki, Carl Holvey, Ross Coomber, Azfer Usmani, Mohammed Sajad, Jonathan Hoare, James J Rucker, Michael Platt & Mikael H Sodergren. (2022) UK Medical Cannabis registry: an analysis of clinical outcomes of medicinal cannabis therapy for chronic pain conditions. Expert Review of Clinical Pharmacology 15:4, pages 473-485.
Read now
Read now
José María Prieto González & Carlos Vila Silván. (2021) Safety and tolerability of nabiximols oromucosal spray: a review of real-world experience in observational studies, registries, and case reports. Expert Review of Neurotherapeutics 21:5, pages 547-558.
Read now
Read now
Sven Gottschling, Oyedeji Ayonrinde, Arun Bhaskar, Marc Blockman, Oscar D’Agnone, Danial Schecter, Luis David Suárez Rodríguez, Sherry Yafai & Claude Cyr. (2020) Safety Considerations in Cannabinoid-Based Medicine. International Journal of General Medicine 13, pages 1317-1333.
Read now
Read now
Michael A Ueberall, Ute Essner & Gerhard HH Mueller-Schwefe. (2019) Effectiveness and tolerability of THC:CBD oromucosal spray as add-on measure in patients with severe chronic pain: analysis of 12-week open-label real-world data provided by the German Pain e-Registry. Journal of Pain Research 12, pages 1577-1604.
Read now
Read now
Mauro Maccarrone, Rafael Maldonado, Miguel Casas, Thomas Henze & Diego Centonze. (2017) Cannabinoids therapeutic use: what is our current understanding following the introduction of THC, THC:CBD oromucosal spray and others?. Expert Review of Clinical Pharmacology 10:4, pages 443-455.
Read now
Read now
Articles from other publishers (24)
Carmen Martinez-PazEmilio García-Cabrera & Ángel Vilches-Arenas. (2023) Effectiveness and Safety of Cannabinoids as an Add-On Therapy in the Treatment of Resistant Spasticity in Multiple Sclerosis: A Systematic Review. Cannabis and Cannabinoid Research 8:4, pages 580-588.
Crossref
Crossref
Mehmet Ergisi, Simon Erridge, Michael HarrisMichal KawkaDevaki NimalanOliver SalazarKaterina LoupasakiRayyan AliCarl HolveyRoss CoomberAzfer UsmaniMohammed SajadSushil BeriJonathan HoareShaheen A. KhanMark W. WeatherallMichael PlattJames J. RuckerMikael H. Sodergren. (2022) An Updated Analysis of Clinical Outcome Measures Across Patients From the UK Medical Cannabis Registry. Cannabis and Cannabinoid Research.
Crossref
Crossref
Marie D’hooghe, Barbara Willekens, Valerie Delvaux, Miguel D’haeseleer, Daniel Guillaume, Guy Laureys, Guy Nagels, Patrick Vanderdonckt, Vincent Van Pesch & Veronica Popescu. (2021) Sativex® (nabiximols) cannabinoid oromucosal spray in patients with resistant multiple sclerosis spasticity: the Belgian experience. BMC Neurology 21:1.
Crossref
Crossref
Michal Kawka, Simon Erridge, Carl Holvey, Ross Coomber, Azfer Usmani, Mohammad Sajad, Michael W. Platt, James J. Rucker & Mikael H. Sodergren. (2021) Clinical Outcome Data of First Cohort of Chronic Pain Patients Treated With Cannabis‐Based Sublingual Oils in the United Kingdom: Analysis From the UK Medical Cannabis Registry. The Journal of Clinical Pharmacology 61:12, pages 1545-1554.
Crossref
Crossref
Daniel Perkins, Hugh Brophy, Iain S. McGregor, Paula O'Brien, Julia Quilter, Luke McNamara, Jerome Sarris, Mark Stevenson, Penny Gleeson, Justin Sinclair & Paul Dietze. (2021) Medicinal cannabis and driving: the intersection of health and road safety policy. International Journal of Drug Policy 97, pages 103307.
Crossref
Crossref
Simon Erridge, Oliver Salazar, Michal Kawka, Carl Holvey, Ross Coomber, Azfer Usmani, Mohammed Sajad, Sushil Beri, Jonathan Hoare, Shaheen Khan, Mark W. Weatherall, Michael Platt, James J. Rucker & Mikael H. Sodergren. (2021) An initial analysis of the UK Medical Cannabis Registry: Outcomes analysis of first 129 patients. Neuropsychopharmacology Reports 41:3, pages 362-370.
Crossref
Crossref
Mark Oppe, Daniela Ortín-Sulbarán, Carlos Vila Silván, Anabel Estévez-Carrillo & Juan M. Ramos-Goñi. (2021) Cost-effectiveness of adding Sativex® spray to spasticity care in Belgium: using bootstrapping instead of Monte Carlo simulation for probabilistic sensitivity analyses. The European Journal of Health Economics 22:5, pages 711-721.
Crossref
Crossref
Friedemann Paul & Carlos Vila Silván. (2021) Effect of nabiximols on Goal Attainment Scale scores in patients with treatment-resistant multiple sclerosis spasticity. Neurodegenerative Disease Management 11:2, pages 143-153.
Crossref
Crossref
Joseph L. Damstra‐Oddy, Eleanor C. Warren, Christopher J. Perry, Yann Desfougères, John‐Mark K. Fitzpatrick, Judith Schaf, Lisa Costelloe, William Hind, Eric J. Downer, Adolfo Saiardi & Robin S.B. Williams. (2021) Phytocannabinoid‐dependent mTORC1 regulation is dependent upon inositol polyphosphate multikinase activity. British Journal of Pharmacology 178:5, pages 1149-1163.
Crossref
Crossref
Dennis J. Sholler, Marilyn A. Huestis, Benjamin Amendolara, Ryan Vandrey & Ziva D. Cooper. (2020) Therapeutic potential and safety considerations for the clinical use of synthetic cannabinoids. Pharmacology Biochemistry and Behavior 199, pages 173059.
Crossref
Crossref
Myfanwy Graham, Catherine J. Lucas, Jennifer Schneider, Jennifer H. Martin & Wayne Hall. (2020) Translational hurdles with cannabis medicines. Pharmacoepidemiology and Drug Safety 29:10, pages 1325-1330.
Crossref
Crossref
Clara Grazia Chisari, Claudio Solaro, Pasquale Annunziata, Roberto Bergamaschi, Assunta Bianco, Simona Bonavita, Vincenzo Brescia Morra, Roberto Bruno Bossio, Elisabetta Capello, Letizia Castelli, Paola Cavalla, Gianfranco Costantino, Diego Centonze, Salvatore Cottone, Maura Chiara Danni, Federica Esposito, Alberto Gajofatto, Claudio Gasperini, Angelica Guareschi, Roberta Lanzillo, Giacomo Lus, Giorgia Teresa Maniscalco, Manuela Matta, Damiano Paolicelli, Loredana Petrucci, Simona Pontecorvo, Isabella Righini, Marco Rovaris, Edoardo Sessa, Gabriella Spinicci, Daniele Spitaleri, Paola Valentino, Mauro Zaffaroni, Mario Zappia & Francesco Patti. (2020) Nabiximols discontinuation rate in a large population of patients with multiple sclerosis: a 18-month multicentre study. Journal of Neurology, Neurosurgery & Psychiatry 91:9, pages 914-920.
Crossref
Crossref
Zaid H. Maayah, Shingo Takahara, Mourad Ferdaoussi & Jason R. B. Dyck. (2020) The anti-inflammatory and analgesic effects of formulated full-spectrum cannabis extract in the treatment of neuropathic pain associated with multiple sclerosis. Inflammation Research 69:6, pages 549-558.
Crossref
Crossref
Kent E. HutchisonSarah L. HagertyJeffrey GalinkinAngela D. BryanL. Cinnamon Bidwell. (2019) Cannabinoids, Pain, and Opioid Use Reduction: The Importance of Distilling and Disseminating Existing Data. Cannabis and Cannabinoid Research 4:3, pages 158-164.
Crossref
Crossref
Hayes Wong & Brian E. Cairns. (2019) Cannabidiol, cannabinol and their combinations act as peripheral analgesics in a rat model of myofascial pain. Archives of Oral Biology 104, pages 33-39.
Crossref
Crossref
Francesco Patti. (2019) Newest evidence for tetrahydrocannabinol:cannabidiol oromucosal spray from postapproval pragmatic studies. Neurodegenerative Disease Management 9:2s, pages 3-7.
Crossref
Crossref
Katja Akgün, Ute Essner, Cordula Seydel & Tjalf Ziemssen. (2019) Daily Practice Managing Resistant Multiple Sclerosis Spasticity With Delta-9-Tetrahydrocannabinol: Cannabidiol Oromucosal Spray: A Systematic Review of Observational Studies. Journal of Central Nervous System Disease 11, pages 117957351983199.
Crossref
Crossref
Elisabeth G. Celius & Carlos Vila. (2018) The influence of THC:CBD oromucosal spray on driving ability in patients with multiple sclerosis-related spasticity. Brain and Behavior 8:5, pages e00962.
Crossref
Crossref
Laura Colino, Javier Herranz-Herrer, Elena Gil-Benito, Teresa Ponte-Lopez, Pablo del Sol-Calderon, Maria Rodrigo-Yanguas, María Gil-Ligero, Antonio J. Sánchez-López, Jose de Leon & Hilario Blasco-Fontecilla. (2018) Cannabinoid Receptors, Mental Pain and Suicidal Behavior: a Systematic Review. Current Psychiatry Reports 20:3.
Crossref
Crossref
Ralf Linker. (2017) What's new in multiple sclerosis spasticity research? Poster session highlights. Neurodegenerative Disease Management 7:6s, pages 51-53.
Crossref
Crossref
Guillermo Izquierdo. (2017) Multiple sclerosis symptoms and spasticity management: new data. Neurodegenerative Disease Management 7:6s, pages 7-11.
Crossref
Crossref
Sabrina Giacoppo, Placido Bramanti & Emanuela Mazzon. (2017) Sativex in the management of multiple sclerosis-related spasticity: An overview of the last decade of clinical evaluation. Multiple Sclerosis and Related Disorders 17, pages 22-31.
Crossref
Crossref
Gillian M. Keating. (2017) Delta-9-Tetrahydrocannabinol/Cannabidiol Oromucosal Spray (Sativex®): A Review in Multiple Sclerosis-Related Spasticity. Drugs 77:5, pages 563-574.
Crossref
Crossref
. (2017) Nabiximols. Reactions Weekly 1635:1, pages 228-228.
Crossref
Crossref